Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

New drug delivered through skin effective in treatment of breast cancer

A drug that has proven effective in the prevention and treatment of breast cancer, but with serious side-effects, may be delivered effectively through the skin using a new topical drug-delivery system.

11 Jul 2014

Genentech agrees to acquire Seragon Pharmaceuticals

Genentech, a member of the Roche Group, today announced it has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.

2 Jul 2014

Conventional fertility hormones do not increase risk of breast, gynecological cancers

There is "little evidence" that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a substantial 30-year follow-up study.

30 Jun 2014

Researchers identify two classes of anti-depressants that reduce symptoms of depression

Depression is common in cancer, up to half of all patients facing the disease experience depressive symptoms, ranging from mild to severe. When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide.

28 Jun 2014

Researchers perform systematic review to identify best treatments for cancer-related depression

27 Jun 2014

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

18 Jun 2014

Research roundup: Funding for safety-net hospitals; insurance competition

Safety-net hospitals rely on disproportionate-share hospital (DSH) payments to help cover uncompensated care costs and underpayments by Medicaid

9 Jun 2014

Personalized treatment approach may benefit patients with common breast cancer subtype

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by scientists at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

7 Apr 2014

Women with BRCA1 mutations may have increased risk for rare types of aggressive uterine cancer

Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Tampa, Fla., March 22-25.

25 Mar 2014

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.

25 Mar 2014

Genetic testing may help select women with ER+ breast cancer for extended hormone therapy

Genetic analyses of results from 1125 postmenopausal women being treated for oestrogen responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from ten years of hormone therapy rather than five.

19 Mar 2014

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013.

4 Mar 2014

Second common type of breast cancer appears to be good candidate for personalized treatment approach

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.

26 Feb 2014

Researchers develop screening assay that quickly assesses nearly 1,500 compounds' effect on estrogen

A team of researchers at City of Hope has developed a screening assay that can quickly assess up to 1,536 compounds' effect on estrogen activity in the body. The test can also evaluate whether chemicals act as inhibitors of aromatase, an enzyme linked to breast cancer that converts androgen to estrogen.

20 Feb 2014

Tamoxifen drug appears to kill fungus associated with deadly brain infection

The drug tamoxifen appears to kill a fungus associated with a deadly brain infection that afflicts HIV/AIDS patients, according to a University of Rochester study published online today by mBio, the journal of the American Society for Microbiology.

11 Feb 2014

Drug used for treating breast cancer also kills fungal disease

Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio-, the online open-access journal of the American Society for Microbiology (ASM.)

11 Feb 2014

Moderate radiation doses can kill premalignant cells and prevent second breast cancers

Survivors of breast cancer have a one in six chance of developing breast cancer in the other breast. But a study conducted in mice suggests that survivors can dramatically reduce that risk through treatment with moderate doses of radiation to the unaffected breast at the same time that they receive radiation therapy to their affected breast.

24 Jan 2014

First Edition: January 10, 2014

Today's headlines include reports about Maryland's plan to reduce hospital spending.

10 Jan 2014

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

14 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013